Accelrys and the Cambridge Crystallographic Data Centre Integrate the Cambridge Structural Database System with Materials Studio 4.1
News Jan 05, 2007
Accelrys has announced the integration of Materials Studio® 4.1, a comprehensive suite of PC-based modeling and simulation solutions for studying a wide range of materials properties and processes, with the Cambridge Structural Database (CSD), a principal product of the Cambridge Crystallographic Data Centre (CCDC).
The integration of Materials Studio and the CSD allows for initiation of a CSD search directly from Materials Studio, providing rapid access to atomic coordinate and other information relating to more than 400,000 crystal structures.
Alternatively, a substructure query prepared in Materials Studio can be automatically transferred to CCDC's ConQuest interface for subsequent database searches that take advantage of ConQuest's extended search capabilities.
Post-search analysis can be conducted in either Materials Studio or ConQuest. Crystallization plays an important role in various industries as a large-scale technique for separation, purification and structure determination.
Many compounds are either sold in their crystalline state or at least crystallized at some point during their production process. Knowledge of crystal structures is a prerequisite for the rational understanding of the solid-state properties of new materials.
Crystal structure determination is also required for reliable patent protection of new products. Dr. Frank Allen, Executive Director of the CCDC, is enthusiastic about the integration with Materials Studio: "The CSD is recognized as the world's repository of organic and metal-organic crystal structure data, holding more than 400,000 structures, with over 30,000 new structures archived annually.
The integration of the CSD System with Materials Studio provides access to this evaluated data source on the desktops of materials scientists worldwide. When combined with the tools in Materials Studio, the availability of these data will lead to improved productivity and the faster solution of problems related to crystalline states."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019